Investors seem to be cool towards unproven molecular diagnostics companies. BG Medicine has had...

|By:, SA News Editor

Investors seem to be cool towards unproven molecular diagnostics companies. BG Medicine has had to once again lower its expectations for its IPO. BG Medicine intends to use the proceeds to help fund the launch of a new diagnostic test for chronic heart failure.